Dihydroergotamine Mesylate and Rozlytrek
Determining the interaction of Dihydroergotamine Mesylate and Rozlytrek and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with entrectinib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 3A4 by entrectinib. The interaction may be particularly important for sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index. When oral midazolam, a sensitive CYP450 3A4 substrate, was administered with entrectinib 600 mg once daily, midazolam peak plasma concentration (Cmax) decreased by 21% but systemic exposure (AUC) increased by 50%. These results suggest weak inhibition of CYP450 3A4 by entrectinib. MANAGEMENT: Caution may be advisable when entrectinib is used with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., ergot alkaloids, colchicine, fentanyl, lovastatin, macrolide immunosuppressants, midazolam, sildenafil, simvastatin, triazolam, vardenafil, vinca alkaloids). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever entrectinib is added to or withdrawn from therapy. References "Product Information. Rozlytrek (entrectinib)." Genentech, South San Francisco, CA.
Professional:MONITOR: Coadministration with entrectinib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 3A4 by entrectinib. The interaction may be particularly important for sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index. When oral midazolam, a sensitive CYP450 3A4 substrate, was administered with entrectinib 600 mg once daily, midazolam peak plasma concentration (Cmax) decreased by 21% but systemic exposure (AUC) increased by 50%. These results suggest weak inhibition of CYP450 3A4 by entrectinib.
MANAGEMENT: Caution may be advisable when entrectinib is used with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., ergot alkaloids, colchicine, fentanyl, lovastatin, macrolide immunosuppressants, midazolam, sildenafil, simvastatin, triazolam, vardenafil, vinca alkaloids). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever entrectinib is added to or withdrawn from therapy.
- "Product Information. Rozlytrek (entrectinib)." Genentech, South San Francisco, CA.
Generic Name: dihydroergotamine
Brand name: DHE. 45, Migranal
Synonyms: Dihydroergotamine (injection), Dihydroergotamine
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Dihydroergotamine Mesylate-Ru-Hist Forte
- Dihydroergotamine Mesylate-Ru-Hist-D
- Dihydroergotamine Mesylate-Rubella and mumps virus vaccine live Intramuscular
- Dihydroergotamine Mesylate-Rubella virus vaccine, live Subcutaneous
- Dihydroergotamine Mesylate-Rubex
- Dihydroergotamine Mesylate-Rubraca
- Rozlytrek-Dihydroergotamine nasal
- Rozlytrek-Dihydroergotamine Nasal Spray
- Rozlytrek-Dilacor XR
- Rozlytrek-Dilantin
- Rozlytrek-Dilantin Infatabs
- Rozlytrek-Dilantin injection